Stem Cell Technology for Neurodegenerative Diseases

Overview

Journal Ann Neurol

Specialty Neurology

Date 2011 Sep 10

PMID 21905078

Citations 102

Authors

J Simon Lunn

Stacey A Sakowski

Junguk Hur

Eva L Feldman

Affiliations

Soon will be listed here.

Abstract

Over the past 20 years, stem cell technologies have become an increasingly attractive option to investigate and treat neurodegenerative diseases. In the current review, we discuss the process of extending basic stem cell research into translational therapies for patients suffering from neurodegenerative diseases. We begin with a discussion of the burden of these diseases on society, emphasizing the need for increased attention toward advancing stem cell therapies. We then explain the various types of stem cells utilized in neurodegenerative disease research, and outline important issues to consider in the transition of stem cell therapy from bench to bedside. Finally, we detail the current progress regarding the applications of stem cell therapies to specific neurodegenerative diseases, focusing on Parkinson disease, Huntington disease, Alzheimer disease, amyotrophic lateral sclerosis, and spinal muscular atrophy. With a greater understanding of the capacity of stem cell technologies, there is growing public hope that stem cell therapies will continue to progress into realistic and efficacious treatments for neurodegenerative diseases.

Citing Articles

Advances in Stem Cell Therapy for Huntington's Disease: A Comprehensive Literature Review.

Shah S, Mansour H, Lucke-Wold B Cells. 2025; 14(1.

PMID: 39791743 PMC: 11719515. DOI: 10.3390/cells14010042.

Stem Cell Therapy and Thiamine Deficiency-Induced Brain Damage.

Hazell A Neurochem Res. 2024; 49(6):1450-1467.

PMID: 38720090 DOI: 10.1007/s11064-024-04137-5.

Role and limitation of cell therapy in treating neurological diseases.

Li Y, Li P, Tao Q, Abuqeis I, Xiyang Y Ibrain. 2024; 10(1):93-105.

PMID: 38682022 PMC: 11045202. DOI: 10.1002/ibra.12152.

An integrative systems-biology approach defines mechanisms of Alzheimer's disease neurodegeneration.

Leventhal M, Zanella C, Kang B, Peng J, Gritsch D, Liao Z bioRxiv. 2024; .

PMID: 38559190 PMC: 10980014. DOI: 10.1101/2024.03.17.585262.

Understanding, engineering, and modulating the growth of neural networks: An interdisciplinary approach.

Raj V, Jagadish C, Gautam V Biophys Rev (Melville). 2024; 2(2):021303.

PMID: 38505122 PMC: 10903502. DOI: 10.1063/5.0043014.

References

Wichterle H, Lieberam I, Porter J, Jessell T . Directed differentiation of embryonic stem cells into motor neurons. Cell. 2002; 110(3):385-97. DOI: 10.1016/s0092-8674(02)00835-8. View

Freeman T, Cicchetti F, Bachoud-Levi A, Dunnett S . Technical factors that influence neural transplant safety in Huntington's disease. Exp Neurol. 2010; 227(1):1-9. DOI: 10.1016/j.expneurol.2010.08.031. View

Drapeau E, Abrous D . Stem cell review series: role of neurogenesis in age-related memory disorders. Aging Cell. 2008; 7(4):569-89. PMC: 2990912. DOI: 10.1111/j.1474-9726.2008.00369.x. View

Yan J, Xu L, Welsh A, Chen D, Hazel T, Johe K . Combined immunosuppressive agents or CD4 antibodies prolong survival of human neural stem cell grafts and improve disease outcomes in amyotrophic lateral sclerosis transgenic mice. Stem Cells. 2006; 24(8):1976-85. DOI: 10.1634/stemcells.2005-0518. View

Lunn J, Hefferan M, Marsala M, Feldman E . Stem cells: comprehensive treatments for amyotrophic lateral sclerosis in conjunction with growth factor delivery. Growth Factors. 2009; 27(3):133-40. DOI: 10.1080/08977190902814855. View

Ilieva H, Polymenidou M, Cleveland D . Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol. 2009; 187(6):761-72. PMC: 2806318. DOI: 10.1083/jcb.200908164. View

Xuan A, Long D, Gu H, Yang D, Hong L, Leng S . BDNF improves the effects of neural stem cells on the rat model of Alzheimer's disease with unilateral lesion of fimbria-fornix. Neurosci Lett. 2008; 440(3):331-5. DOI: 10.1016/j.neulet.2008.05.107. View

Laganiere J, Kells A, Lai J, Guschin D, Paschon D, Meng X . An engineered zinc finger protein activator of the endogenous glial cell line-derived neurotrophic factor gene provides functional neuroprotection in a rat model of Parkinson's disease. J Neurosci. 2010; 30(49):16469-74. PMC: 6634881. DOI: 10.1523/JNEUROSCI.2440-10.2010. View

Hussein S, Batada N, Vuoristo S, Ching R, Autio R, Narva E . Copy number variation and selection during reprogramming to pluripotency. Nature. 2011; 471(7336):58-62. DOI: 10.1038/nature09871. View

10.

Cho G, Noh M, Kim H, Koh S, Kim K, Kim S . Bone marrow-derived stromal cells from amyotrophic lateral sclerosis patients have diminished stem cell capacity. Stem Cells Dev. 2009; 19(7):1035-42. DOI: 10.1089/scd.2009.0453. View

11.

Xu L, Ryugo D, Pongstaporn T, Johe K, Koliatsos V . Human neural stem cell grafts in the spinal cord of SOD1 transgenic rats: differentiation and structural integration into the segmental motor circuitry. J Comp Neurol. 2009; 514(4):297-309. PMC: 2727711. DOI: 10.1002/cne.22022. View

12.

Lefebvre S, Burlet P, Liu Q, Bertrandy S, Clermont O, Munnich A . Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet. 1997; 16(3):265-9. DOI: 10.1038/ng0797-265. View

13.

Cooper O, Hargus G, Deleidi M, Blak A, Osborn T, Marlow E . Differentiation of human ES and Parkinson's disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid. Mol Cell Neurosci. 2010; 45(3):258-66. PMC: 2945816. DOI: 10.1016/j.mcn.2010.06.017. View

14.

Shruster A, Melamed E, Offen D . Neurogenesis in the aged and neurodegenerative brain. Apoptosis. 2010; 15(11):1415-21. DOI: 10.1007/s10495-010-0491-y. View

15.

Clelland C, Barker R, Watts C . Cell therapy in Huntington disease. Neurosurg Focus. 2008; 24(3-4):E9. DOI: 10.3171/FOC/2008/24/3-4/E8. View

16.

Hargus G, Cooper O, Deleidi M, Levy A, Lee K, Marlow E . Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci U S A. 2010; 107(36):15921-6. PMC: 2936617. DOI: 10.1073/pnas.1010209107. View

17.

Tuszynski M, Thal L, Pay M, Salmon D, U H, Bakay R . A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med. 2005; 11(5):551-5. DOI: 10.1038/nm1239. View

18.

Lunn J, Sakowski S, Federici T, Glass J, Boulis N, Feldman E . Stem cell technology for the study and treatment of motor neuron diseases. Regen Med. 2011; 6(2):201-13. PMC: 3154698. DOI: 10.2217/rme.11.6. View

19.

Suzuki M, McHugh J, Tork C, Shelley B, Hayes A, Bellantuono I . Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol Ther. 2008; 16(12):2002-10. PMC: 2678899. DOI: 10.1038/mt.2008.197. View

20.

Garbayo E, Montero-Menei C, Ansorena E, Lanciego J, Aymerich M, Blanco-Prieto M . Effective GDNF brain delivery using microspheres--a promising strategy for Parkinson's disease. J Control Release. 2009; 135(2):119-26. DOI: 10.1016/j.jconrel.2008.12.010. View